Key result
Addition of SGLT2 inhibitors to optimized therapy in 60 outpatients with HFrEF was associated with significant improvement in left and right ventricular function at 3, 6, and 12 months.
Why the study?
The study aimed to evaluate the effects of SGLT2 inhibitors on echocardiographic parameters of left and right ventricular function in outpatients with a long history of HFrEF on optimized therapy.
Do SGLT2 inhibitors improve echocardiographic parameters of left and right ventricular function in outpatients with HFrEF on optimized therapy?
Cohort (n=60)
Do SGLT2 inhibitors improve echocardiographic parameters of left and right ventricular function in outpatients with HFrEF on optimized therapy?
The addition of SGLT2 inhibitors to optimized therapy in HFrEF patients is associated with significant improvements in both left and right ventricular function, providing mechanistic insight into their clinical benefits.
May support SGLT2i addition for ventricular function in HFrEF; hypothesis-generating and requires RCT confirmation before practice change.
BACKGROUND: Type 2 sodium-glucose cotransporter inhibitors (SGLT2i) are among the main therapeutic options for patients with chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effects of SGLT2i on the echocardiographic parameters of left (LV) and right (RV) ventricular function among outpatients with a long history of HFrEF, in optimized therapy. METHODS: We evaluated consecutive patients affected by HFrEF in whom the SGLT2i therapy was prescribed. Following a baseline evaluation (T0), in which SGLT2i was prescribed, patients were re-evaluated at 3 (T3), 6 (T6), and 12 (T12) months. RESULTS: We considered 60 patients for the analysis with a median history of HFrEF of more than seven years in optimal medical and electrical therapy. After SGLT2i therapy, LV ejection fraction and LV global longitudinal strain improved from baseline at T3, T6, and T12. Analogously, RV global and free wall longitudinal strain improved at T3 and T6. CONCLUSIONS: Our study shows that the addition of SGLT2i to the optimized therapy for HFrEF was associated with a significant improvement in both LV and RV function, thus highlighting a possible mechanism responsible for the benefit obtained with this class of drugs.
No takes yet. Share an insight, caveat, or question.
Alcidi et al. (2023) conducted a cohort in heart failure with reduced ejection fraction (HFrEF) (n=60). SGLT2 inhibitors vs. baseline was evaluated on echocardiographic parameters of left (LV) and right (RV) ventricular function. Addition of SGLT2 inhibitors to optimized therapy in 60 outpatients with HFrEF was associated with significant improvement in left and right ventricular function at 3, 6, and 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: